Cyclophosphamide Monohydrate

• An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerabilit… Pending
  2023-506865-71-00 Phase I (FiH) 4 countries CanCell Therapeutics
• Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis - the IDEAL trial Pending
  2024-517303-36-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
• RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy… Pending
  2025-521145-24-01 Phase I/II 3 countries Cabaletta Bio Inc.
• A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending
  2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
• A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting
  2022-501607-27-00 Phase I (FiH) 3 countries Cellectis
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting
  2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting
  2024-510778-26-00 Phase II 6 countries Iovance Biotherapeutics Inc.
• A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting
  2024-514084-26-00 Phase III 3 countries Ascentage Pharma Group Inc.
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 Phase III 19 countries Princess Maxima Center For Pediatric Oncology
• A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autol… Recruiting
  2025-521227-70-00 Phase I (FiH) 1 country CuraCell Holding AB
• A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i… Recruiting
  2023-507613-10-01 Phase I (FiH) 2 countries Cabaletta Bio Inc.
• Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in p… Recruiting
  2024-514031-20-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
• IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting
  2024-519790-19-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting
  2023-506400-99-00 Phase II 3 countries Vall D Hebron Institute Of Oncology
• Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Recruiting
  2024-515624-36-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting
  2023-508902-66-00 Phase II 1 country Amsterdam UMC
• Metronomic neoadjuvant capecitabine and cyclophosphamide in huge (PCI>28) Pseudomyxoma peritonei (PMP) patients candidates to cytoreductive … Recruiting
  2024-514329-42-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
• not applicable Recruiting
  2023-508953-16-00 Phase II 1 country Nationwide Childrens Hospital
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 Phase II 1 country Grupo Espanol De Leucemia Linfocitica Cronica
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau… Recruiting
  2024-514544-90-00 Phase I/II 1 country Fundacion De Investigacion Biomedica De Salamanca
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 Phase IV 2 countries Lysarc
• A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study Ended
  2023-504632-17-00 Phase II 1 country Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended
  2023-510178-15-00 Phase III 17 countries Celgene Corp.
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended
  2023-503452-27-00 Phase III 7 countries Novartis Pharma AG

Showing 1–24 of 37 trials